SAB Biotherapeutics (SABS) Leases: 2020-2025
Historic Leases for SAB Biotherapeutics (SABS) over the last 4 years, with Sep 2025 value amounting to $3.5 million.
- SAB Biotherapeutics' Leases fell 2.41% to $3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 2.41%. This contributed to the annual value of $3.6 million for FY2024, which is 2.37% down from last year.
- As of Q3 2025, SAB Biotherapeutics' Leases stood at $3.5 million, which was down 0.61% from $3.5 million recorded in Q2 2025.
- SAB Biotherapeutics' 5-year Leases high stood at $4.0 million for Q4 2021, and its period low was $3.5 million during Q3 2025.
- Over the past 3 years, SAB Biotherapeutics' median Leases value was $3.6 million (recorded in 2024), while the average stood at $3.6 million.
- Data for SAB Biotherapeutics' Leases shows a maximum YoY declined of 5.83% (in 2023) over the last 5 years.
- SAB Biotherapeutics' Leases (Quarterly) stood at $4.0 million in 2021, then decreased by 3.05% to $3.9 million in 2022, then dropped by 5.83% to $3.7 million in 2023, then declined by 2.37% to $3.6 million in 2024, then decreased by 2.41% to $3.5 million in 2025.
- Its Leases stands at $3.5 million for Q3 2025, versus $3.5 million for Q2 2025 and $3.6 million for Q1 2025.